In vitro: Synergistic anti-proliferation, apoptosis (↑caspase-3, PARP cleavage), AKT/MAPK inhibition;In vivo: Tumor volume (-vs monotherapy, p < 0.05), lung nodules (-p < 0.01). This evidence concerns the gene AKT1 and neoplasm.